Oragenics Inc. (OGEN)

Business: Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

IPO Date: 25-Feb-2004

Exec. Chairman: Dr. Frederick W. Telling Ph.D.

CFO, Sec., Treasurer & Interim Principal Exec. Officer: Mr. Michael O. Sullivan CPA

Listing: NYSE: OGEN

Country: United States

Headquarters: Tampa, FL

Website: https://www.oragenics.com

Market cap: $38.91 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-16.53 Mln

Cash: $21.37 Mln

Total Debt: $0.57 Mln

Insider's Holding: 3.90%

Liquidity: Low

52 Week range: $0.22 - 1.15

Shares outstanding: 116,395,000

10 Years Aggregate:

• CFO: $-88.59 Mln
• EBITDA: $-129.04 Mln
• Net Profit: $-128.03 Mln